Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22280407 | 0.84 | SMN1; SMN2 (0.36) | SMN1; SMN2HRH3ALDH1A1LMNA | |
| SCHEMBL24041204 | 0.83 | SOS1 (0.31) | — | |
| SCHEMBL23822993 | 0.82 | SIGMAR1 (0.33) | KMT2AMEN1 | |
| SCHEMBL12030768 | 0.80 | HRH3 (0.40) | SMN1; SMN2HRH3ALDH1A1HPGD | |
| SCHEMBL25066719 | 0.80 | HRH3 (0.42) | KMT2AMEN1HRH3 | |
| SCHEMBL20234622 | 0.79 | SIGMAR1 (0.32) | KMT2AMEN1 | |
| SCHEMBL24179813 | 0.79 | SIGMAR1 (0.35) | KMT2AMEN1HRH3 | |
| SCHEMBL21564194 | 0.78 | KMT2A (0.42) | SMN1; SMN2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL643674 | 0.78 | KMT2A (0.42) | SMN1; SMN2KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL23108665 | 0.78 | KMT2A (0.42) | SMN1; SMN2KMT2AMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | SMN1; SMN2 978/4885KMT2A 1251/4885MEN1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.